United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 75 Shares
by Jessica Moore · The Cerbat GemUnited Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 75 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $536.95, for a total transaction of $40,271.25. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $174,209,668.85. The trade was a 0.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Stock Performance
United Therapeutics stock opened at $580.51 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The firm has a market cap of $25.44 billion, a PE ratio of 20.81, a P/E/G ratio of 1.65 and a beta of 0.75. The firm’s 50 day moving average price is $524.67 and its two-hundred day moving average price is $488.35.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the business posted $6.19 EPS. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the company. Wells Fargo & Company boosted their target price on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Morgan Stanley increased their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Royal Bank Of Canada raised their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $601.50.
Check Out Our Latest Research Report on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $277,000. Cerity Partners LLC lifted its position in shares of United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia boosted its stake in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the period. Institutional investors own 94.08% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.